Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Covant oral small molecule FcRn inhibitor
- Development stage
- Preclinical
- Lead developer
- Covant Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Covant Therapeutics is developing an oral small molecule allosteric modulator of the neonatal Fc receptor (FcRn). This drug candidate is designed to inhibit the recycling of immunoglobulin G (IgG) by FcRn, which leads to a reduction in the levels of circulating pathogenic IgG antibodies. It is being developed for the treatment of various IgG-mediated autoimmune diseases, including generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP). As an oral therapy, it is intended to provide a more accessible and convenient alternative to current injectable FcRn-targeting biologics. The program is currently in the hit-to-lead preclinical stage of development.
- Other names
- Oral Small Molecule FcRn Inhibitor
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on Covant oral small molecule FcRn inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covant oral small molecule FcRn inhibitor.